Famitinib

Generic Name: Famitinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 1044040-56-3

Unique Ingredient Identifier: 768FW21J3L

Background: Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Phase 2

Recruiting

Conditions: Sarcomatoid Carcinoma of Lung

Interventions: Drug: Camrelizumab
Drug: Famitinib

First Posted Date: 2021-05-17

Last Posted Date: 2024-09-30

Lead Sponsor: Qian Chu

Target Recruit Count: 28

Registration Number: NCT04888429

Locations: 🇨🇳
The first Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China

and more 5 locations

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Phase 2

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: SHR6390
Drug: famitinib

First Posted Date: 2021-02-02

Last Posted Date: 2023-04-13

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 35

Registration Number: NCT04733417

Locations: 🇨🇳
Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Phase 1

Conditions: Solid Tumor

Interventions: Biological: SHR-1701
Drug: Famitinib

First Posted Date: 2020-12-22

Last Posted Date: 2022-01-26

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 222

Registration Number: NCT04679038

Locations: 🇨🇳
General Hospital of Eastern Theater Command, Nanjing, Jiangsu, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 13 locations

A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma

Phase 2

Withdrawn

Conditions: Intrahepatic Cholangiocarcinoma

Interventions: Drug: Famitinib

First Posted Date: 2020-07-21

Last Posted Date: 2021-06-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Registration Number: NCT04479904

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer
Metastatic Cancer

Interventions: Drug: SHR7390
Drug: SHR3162
Drug: Pyrotinib
Drug: Everolimus
Drug: SHR1210
Drug: SHR2554
Drug: SHR6390
Drug: Nab paclitaxel
Drug: SHR3680
Drug: Famitinib
Drug: Capecitabine
Drug: SHR1701
Drug: SERD
Drug: AI
Drug: VEGFi

First Posted Date: 2020-04-21

Last Posted Date: 2022-07-26

Lead Sponsor: Fudan University

Target Recruit Count: 319

Registration Number: NCT04355858

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Phase 2

Completed

Conditions: Solid Tumor

Interventions: Drug: Camrelizumab
Drug: Famitinib

First Posted Date: 2020-04-15

Last Posted Date: 2023-09-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 233

Registration Number: NCT04346381

Locations: 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Phase 1

Withdrawn

Conditions: Effect of Drugs
Pediatric Cancer
Progression

Interventions: Drug: Famitinib
Drug: Camrelizumab
Drug: Ifosfamide

First Posted Date: 2019-08-05

Last Posted Date: 2020-05-19

Lead Sponsor: Peking University People's Hospital

Registration Number: NCT04044378

Locations: 🇨🇳
Lu Xie, Beijing, Beijing, China

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Phase 2

Conditions: Endometrial Cancer
Ovarian Cancer Recurrent
Renal Cell Carcinoma
Urothelial Carcinoma
Cervical Cancer

Interventions: Biological: SHR-1210
Drug: Famitinib

First Posted Date: 2019-02-04

Last Posted Date: 2022-07-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 265

Registration Number: NCT03827837

Locations: 🇨🇳
Huadong Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）

Phase 3

Completed

Conditions: Colorectal Cancer Recurrent
Colorectal Cancer Metastatic

Interventions: Drug: Placebo
Drug: Famitinib

First Posted Date: 2015-03-18

Last Posted Date: 2020-12-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 543

Registration Number: NCT02390947

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
The Third Xiangya Hospital of Cental South University, Changsha, Hunan, China
🇨🇳
Cancer Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China

and more 41 locations

A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Suspended

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Famitinib
Drug: Placebo

First Posted Date: 2015-02-06

Last Posted Date: 2019-11-04

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 137

Registration Number: NCT02356991

Locations: 🇨🇳
Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China
🇨🇳
Cancer Hospital of Guangzhou Sun Yat-sen University, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy